دورية أكاديمية
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
| العنوان: | Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. |
|---|---|
| المؤلفون: | Camus, Vincent, Rossi, Cédric, Sesques, Pierre, Lequesne, Justine, Tonnelet, David, Haioun, Corinne, Durot, Eric, Willaume, Alexandre, Gauthier, Martin, Moles-Moreau, Marie-Pierre, Antier, Chloé, Lazarovici, Julien, Monjanel, Hélène, Bernard, Sophie, Tardy, Magalie, Besson, Caroline, Lebras, Laure, Choquet, Sylvain, Le Du, Katell, Bonnet, Christophe, Bailly, Sarah, Damaj, Ghandi, Laribi, Kamel, Maisonneuve, Hervé, Houot, Roch, Chauchet, Adrien, Jardin, Fabrice, Traverse-Glehen, Alexandra, Decazes, Pierre, Becker, Stéphanie, Berriolo-Riedinger, Alina, Tilly, Hervé |
| المساهمون: | UCL - SSS/DDUV/SIGN - Cell signalling, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie |
| المصدر: | Blood advances, Vol. 5, no. 19, p. 3862-3872 (2021) |
| بيانات النشر: | American Society of Hematology |
| سنة النشر: | 2021 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Large B-Cell, Diffuse, Retrospective Studies, Transplantation, Autologous, Treatment Outcome |
| الوصف: | Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients. The first-line standard of care remains debated. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P < .001); only 17 (5.4%) patients received mediastinal radiotherapy. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P = .23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The median follow-up was 44 months, and the R-ACVBP, R-CHOP14, and R-CHOP21 three-year progression-free survival probabilities were 89.4% (95% confidence interval [CI], 84.8-94.2), 89.4% (95% CI, 82.7-96.6), and 74.7% (95% CI, 64-87.1) (P = .018). A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18; 95% CI, 1.05-4.53). Excess febrile neutropenia (24.4% vs 5.3% vs 5.3%; P < .001) and mucositis (22.8% vs 3.9% vs 1.8%; P < .001) were observed with R-ACVBP compared with the R-CHOP regimens. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. R-ACVBP acute toxicity was higher than that of R-CHOP14. Our data confirmed the prognostic importance of baseline TMTV. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2473-9529 2473-9537 |
| العلاقة: | boreal:262043; http://hdl.handle.net/2078.1/262043Test; info:pmid/34461634; urn:ISSN:2473-9529; urn:EISSN:2473-9537 |
| DOI: | 10.1182/bloodadvances.2021004778 |
| الإتاحة: | https://doi.org/10.1182/bloodadvances.2021004778Test http://hdl.handle.net/2078.1/262043Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.135C4D96 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 24739529 24739537 |
|---|---|
| DOI: | 10.1182/bloodadvances.2021004778 |